Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | TRPV4 | Q9HBA0 | 5/20 | 0.41 |
| ▸ | ITGA1 | P56199 | 3/20 | 0.40 |
| ▸ | FABP4 | P15090 | 1/20 | 0.39 |
| ▸ | IDH1 | O75874 | 3/20 | 0.38 |
| ▸ | CCR1 | P32246 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | CNR1 | P21554 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4132203 | 1.00 | MAPK1 (0.45) | MAPK1TRPV4ITGA1FABP4IDH1 | |
| SCHEMBL14605688 | 0.90 | TRPV4 (0.41) | MAPK1TRPV4ITGA1FABP4CCR1 | |
| SCHEMBL14605764 | 0.90 | TRPV4 (0.43) | MAPK1TRPV4ITGA1FABP4IDH1 | |
| SCHEMBL14605691 | 0.89 | TRPV4 (0.44) | TRPV4ITGA1FABP4IDH1CCR1 | |
| SCHEMBL14606012 | 0.89 | ITGAV (0.41) | MAPK1TRPV4IDH1CCR1CNR1 | |
| SCHEMBL4135486 | 0.88 | CCR1 (0.42) | TRPV4FABP4CCR1MEN1KMT2A | |
| SCHEMBL4142782 | 0.87 | MAPK1 (0.43) | MAPK1TRPV4ITGA1CCR1MEN1 | |
| SCHEMBL14605592 | 0.87 | ALDH1A1 (0.40) | TRPV4MEN1NPC1LMNAMAPT | |
| SCHEMBL13872425 | 0.86 | MAPK1 (0.43) | MAPK1TRPV4ITGA1FABP4IDH1 | |
| SCHEMBL14606011 | 0.86 | CCR1 (0.39) | TRPV4CCR1CNR1ATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090105259-A1 | Acyclic 1,4-Diamines and Uses Thereof | SMITHKLINE BEECHAM CORPORATION | 2009-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105259-A1 | Acyclic 1,4-Diamines and Uses Thereof | TRPV4, TRPC4, TRPV1 | MAPK1 1486/4885TRPV4 1/4885ITGA1 3929/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.